| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.04. | Viracta Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.04. | Viracta Therapeutics, Inc.: Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan | 3 | GlobeNewswire (USA) | ||
| 20.03. | Viracta Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.03. | Viracta Therapeutics Inc reports results for the quarter ended in December - Earnings Summary | 2 | Reuters | ||
| 07.03. | Viracta Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 07.03. | Viracta Therapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 07.03. | Viracta Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 07.03. | Viracta Therapeutics, Inc.: Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | 102 | GlobeNewswire (Europe) | Completed Stage 2 enrollment in the NAVAL-1 trial of Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supporting its speed to market strategy; topline results from... ► Artikel lesen | |
| 06.02. | Viracta Therapeutics, Inc.: Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference | 6 | GlobeNewswire (USA) | ||
| 04.01. | Viracta Therapeutics, Inc.: Viracta Therapeutics Provides Clinical Update and Outlook for 2024 | 302 | GlobeNewswire (Europe) | Speed to market strategy for Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supported by complete enrollment of Stage 1, complete enrollment of Stage 2 anticipated... ► Artikel lesen | |
| 04.12.23 | Viracta Therapeutics, Inc.: Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels | 433 | GlobeNewswire (Europe) | Confirmed partial responses without dose-limiting toxicities during dose escalation along with new preclinical data support the opportunity to further enhance efficacy through a novel split daily... ► Artikel lesen | |
| 17.11.23 | Viracta Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.11.23 | Viracta Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 09.11.23 | Viracta Therapeutics Inc reports results for the quarter ended in September - Earnings Summary | 1 | Reuters | ||
| 09.11.23 | Viracta Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.11.23 | Viracta Therapeutics, Inc.: Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update | 1 | GlobeNewswire (USA) | ||
| 07.11.23 | Viracta Therapeutics, Inc.: Viracta Therapeutics to Present at Upcoming Investor Conferences | 1 | GlobeNewswire (USA) |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 3.680 |
| TESLA | 2.439 |
| DEUTSCHE BANK | 2.183 |
| NEL | 1.666 |
| BYD | 1.510 |
| NVIDIA | 1.335 |
| BAYER | 1.215 |
| TUI | 1.149 |
| RHEINMETALL | 984 |
| SUPER MICRO COMPUTER | 860 |
| AIXTRON SE | 800 |
| COMMERZBANK | 736 |
| BASF | 711 |
| PHILIPS | 676 |
| RWE | 667 |
| MERCEDES-BENZ | 656 |
| DELIVERY HERO | 621 |
| THYSSENKRUPP | 604 |
| HEIDELBERGER DRUCK | 581 |
| JINKOSOLAR | 572 |
| PLUG POWER | 558 |
| AMAZON | 557 |
| SIEMENS ENERGY | 536 |
| META PLATFORMS | 517 |
| RENK GROUP | 493 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
